0001140361-24-035600.txt : 20240802 0001140361-24-035600.hdr.sgml : 20240802 20240802215326 ACCESSION NUMBER: 0001140361-24-035600 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240717 FILED AS OF DATE: 20240802 DATE AS OF CHANGE: 20240802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clemmer James C CENTRAL INDEX KEY: 0001476700 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50761 FILM NUMBER: 241172983 MAIL ADDRESS: STREET 1: COVIDIEN PLC STREET 2: 15 HAMPSHIRE STREET CITY: MANSFIELD STATE: MA ZIP: 02048 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANGIODYNAMICS INC CENTRAL INDEX KEY: 0001275187 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 113146460 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 BUSINESS ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 BUSINESS PHONE: 5187981215 MAIL ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 4 1 form4.xml FORM 4 X0508 4 2024-07-17 0001275187 ANGIODYNAMICS INC ANGO 0001476700 Clemmer James C 14 PLAZA DRIVE LATHAM NY 12110 true true President and CEO false Common Stock 2024-07-17 4 M 0 56279 0 A 690312 D Common Stock 2024-07-17 4 F 0 28730 7.4 D 661582 D Performance Right 2024-07-17 4 M 0 52378 0 A Common Stock 52378 0 D This acquisition of 56,279 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021. The exempt disposition of 28,730 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021. On July 21, 2021, the reporting person received a target grant of 52,378 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 56,279 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited. /s/ Stephen A. Trowbridge, as Attorney in Fact 2024-08-02